
Sign up to save your podcasts
Or
In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease. This special episide is supported by independent educational grant from AstraZeneca.
For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
4.5
8585 ratings
In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease. This special episide is supported by independent educational grant from AstraZeneca.
For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
128 Listeners
314 Listeners
481 Listeners
691 Listeners
282 Listeners
254 Listeners
3,329 Listeners
90 Listeners
1,093 Listeners
693 Listeners
173 Listeners
511 Listeners
320 Listeners
413 Listeners
363 Listeners